Research programme: cathepsin C inhibitors - Merck FrosstAlternative Names: Dipeptidyl-peptidase 1 (DDP-1) inhibitors - Merck Frosst
Latest Information Update: 02 Nov 2009
At a glance
- Originator Merck Frosst
- Mechanism of Action Dipeptidyl peptidase I inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma; Cystic fibrosis
Most Recent Events
- 19 Sep 2007 Preclinical trials in Cystic fibrosis in Canada (unspecified route)
- 19 Sep 2007 Preclinical trials in Asthma in Canada (unspecified route)